Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study
- 7 July 2015
- journal article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 57 (1), 129-133
- https://doi.org/10.3109/10428194.2015.1071492
Abstract
Although the median survival in polycythemia vera (PV) is 14 years, mortality is higher than in an age- and sex-matched population. This study included 3941 PV patients diagnosed between 2000–2012 from Surveillance, Epidemiology and End Results (SEER) 13 registry to determine 5-year survival and the incidence of second primary malignancies (SPM). The actuarial 5 year survival in the overall cohort was 79.5%. The cumulative incidence of SPM was 13.1% at 10 years. SPMs occurred at a standardized incidence ratio (SIR) of 1.29 (95% CI = 1.16–1.43; p < 0.001) with an absolute excess risk (AER) of 42.49 per 10 000 population. A significantly higher risk was noted for acute myeloid leukemia (SIR = 12.24; 95% CI = 8.17–17.8; p-value < 0.001) and chronic myeloid leukemia (SIR = 10.66; 95% CI = 3.75–19.6; p-value < 0.001). Patients with PV are at a high risk of SPM and leukemic transformation, which may compromise long-term survival.This publication has 13 references indexed in Scilit:
- Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosisEuropean Journal of Haematology, 2014
- Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European UnionEuropean Journal of Haematology, 2014
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyLeukemia, 2013
- Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort studyBlood, 2011
- Higher risk of primary cancers after polycythaemia vera and vice versaBritish Journal of Haematology, 2011
- Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 studyLeukemia, 2006
- A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphomaBone Marrow Transplantation, 2006
- Leukemic transformation of polycythemia veraCancer, 2005
- Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational studyBlood, 2005
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988